Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis

Diabetes and Vascular Disease Research

Volumn 6, Issue 4, 2009, Pages 262-268

  Yun, Hu ^a   Guoyu, Tong ^a   Wei, Xu ^a   Jiajia, Pan ^a   Ryan, Kathy ^b   Rongze, Yang ^b   Shuldiner, Alan R ^b   Gong, Da Wei ^b   Dalong, Zhu ^a  

^a NANJING UNIVERSITY   (China)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Adipokines; Anti inflammation; Atherosclerosis; Statin; Type 2 diabetes

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SERUM AMYLOID A; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

ADIPOKINES; ADIPONECTIN; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAROTID ARTERY DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MIDDLE AGED; SERUM AMYLOID A PROTEIN; SIMVASTATIN; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70350163405     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.1177/1479164109339966     Document Type: Article

References (38)

1. Tracy RP (2003) Inflammation, the metabolic syndrome and cardiovascular risk. Int J Clin Pract Suppl 134: 10-17 (Pubitemid 36565031)
2. Koenig W, Sund M, Frohlich M, et al. (1999) C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99: 237-242 (Pubitemid 29056365)
3. Ridker PM, Stampfer MJ, Rifai N (2001) Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285: 2481-2485 (Pubitemid 32433842)
4. Leinonen E, Hurt-Camejo E, Wiklund O, Hulten LM, Hiukka A, Taskinen MR (2003) Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis 166: 387-394 (Pubitemid 36071698)
5. Ridker PM, Danielson E, Fonseca FA, et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195-2207
6. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC (2004) Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 24: 930-934 (Pubitemid 38620874)
7. Langenfeld MR, Forst T, Hohber C, et al. (2005) Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 111: 2525-2531 (Pubitemid 40696142)
8. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S (2001) Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103: 1933-1935 (Pubitemid 32322218)
9. Devaraj S, Chan E, Jialal I (2006) Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab 91: 4489-4496 (Pubitemid 44833428)
10. Kinlay S, Schwartz GG, Olsson AG, et al. (2003) High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 108: 1560-1566 (Pubitemid 37187781)
11. Lefer DJ (2002) Statins as potent antiinflammatory drugs. Circulation 106: 2041-2042
12. Albert MA, Danielson E, Rifai N, Ridker PM (2001) Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286: 64-70. (Pubitemid 32606333)
13. Chan KY, Boucher ES, Gandhi PJ, Silva MA (2004) HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein. Am J Health Syst Pharm 61: 1676-1681
14. Hognestad A, Aukrust P, Wergeland R, et al. (2004) Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation. Clin Cardiol 27: 199-203. (Pubitemid 38451153)
15. Holm T, Andreassen AK, Ueland T, et al. (2001) Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. Am J Cardiol 87: 815-8, A9. (Pubitemid 32209111)
16. Bouloumie A, Casteilla L, Lafontan M (2008) Adipose tissue lymphocytes and macrophages in obesity and insulin resistance: makers or markers, and which comes first? Arterioscler Thromb Vasc Biol 28: 1211-1213
17. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM (1995) Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95: 2409-2415
18. Fried SK, Bunkin DA, Greenberg AS (1998) Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83: 847-850
19. Shimomura I, Funahashi T, Takahashi M, et al. (1996) Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 2: 800-803 (Pubitemid 26225097)
20. Lehrke M, Lazar MA (2004) Inflamed about obesity. Nat Med 10: 126-127
21. Poitou C, Viguerie N, Cancello R, et al. (2005) Serum amyloid A: production by human white adipocyte and regulation by obesity and nutrition. Diabetologia 48: 519-528 (Pubitemid 40487299)
22. Yang RZ, Lee MJ, Hu H, et al. (2006) Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoSMed 3: e287. (Pubitemid 43987831)
23. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. (1997) Diabetes Care 20: 1183-1197
24. Fox CS, Coady S, Sorlie PD, et al. (2004) Trends in cardiovascular complications of diabetes. JAMA 292: 2495-2499 (Pubitemid 39552675)
25. Cubbon R, Kahn M, Kearney MT (2008) Secondary prevention of cardiovascular disease in type 2 diabetes and prediabetes: a cardiologist's perspective. Int J Clin Pract 62: 287-299
26. Haffner SM (2004) Dyslipidemia management in adults with diabetes. Diabetes Care 27(suppl 1): S68-S71.
27. Ali YS, Linton MF, Fazio S (2008) Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia. Curr Opin Endocrinol Diabetes Obes 15: 142-146 (Pubitemid 351651727)
28. Rugina M, Caras I, Jurcut R, et al. (2007) Systemic inflammatory markers in patients with aortic sclerosis. Roum Arch Microbiol Immunol 66: 10-16
29. Magyar MT, Szikszai Z, Balla J, et al. (2003) Early-onset carotid atherosclerosis is associated with increased intima-media thickness and elevated serum levels of inflammatory markers. Stroke 34: 58-63. (Pubitemid 36070801)
30. Benditt EP, Hoffman JS, Eriksen N, Parmelee DC, Walsh KA (1982) SAA, an apoprotein of HDL: its structure and function. Ann N Y Acad Sci 389: 183-189 (Pubitemid 12013188)
31. Wu A, Hinds CJ, Thiemermann C (2004) High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications. Shock 21: 210-221
32. Furlaneto CJ, Campa A (2000) A novel function of serum amyloid A: a potent stimulus for the release of tumor necrosis factor-alpha, interleukin-1beta, and interleukin-8 by human blood neutrophil. Biochem Biophys Res Commun 268: 405-408
33. Thorn CF, Lu ZY, Whitehead AS (2004) Regulation of the human acute phase serum amyloid A genes by tumour necrosis factor-alpha, interleukin-6 and glucocorticoids in hepatic and epithelial cell lines. Scand J Immunol 59: 152-158
34. Walter DH, Fichtischerer S, Britten MB, et al. (2001) Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol 38: 2006-2012
35. Bickel C, Rupprecht HJ, Blankenberg S, et al. (2002) Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 89: 901-908 (Pubitemid 34310284)
36. Okura H, Asawa K, Kubo T, et al. (2007) Impact of statin therapy on systemic inflammation, left ventricular systolic and diastolic function and prognosis in low risk ischemic heart disease patients without history of congestive heart failure. Intern Med 46: 1337-1343 (Pubitemid 47455755)
37. Ky B, Rader DJ (2005) The effects of statin therapy on plasma markers of inflammation in patients without vascular disease. Clin Cardiol 28: 67-70. (Pubitemid 40209377)
38. Johnson BD, Kip KE, Marroquin OC, et al. (2004) Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 109: 726-732